Precursors to Pancreatic Cancer

80 slides · PPTX & PDF available

Download PDF

Request PowerPoint

PowerPoint animations are preserved in the original file.

Slide index (80)

Loading slide titles…

Loading presentation…

Swipe on touchscreens · Use ← / → to change slides, Home / End to jump.

Lecture topics

What is a pancreatic cancer precursor?
Why high-grade PanIN is significant
Telomere dysfunction: Proposed consequence
Classes of alteration in carcinogenesis
PanIN in one conceptual map
IPMN: Typical distribution
Why identifying the precursor phase matters
Source and scope

Slide index & full transcript (80 slides)

Text from the original slides, in presentation order. Diagrams and images remain in the viewer above.

Slide 1 · Precursors to

Pancreatic Cancer

PanIN • IPMN • mucinous cystic neoplasm

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish microscopic PanIN from macroscopic mucinous cystic precursors.

Explain morphologic grading and evidence that PanIN precedes invasive carcinoma.

Relate driver alterations and telomere changes to multistep progression.

Identify clinicopathologic distinctions among PanIN, IPMN, and MCN.

Slide 3 · What is a pancreatic cancer precursor?

Noninvasive neoplasia with potential to become invasive carcinoma

Interpretation

The decisive boundary is whether neoplastic epithelium remains confined to a preexisting duct or cyst, rather than infiltrating surrounding tissue.

Slide 4 · Three precursor pathways

PanIN

Microscopic lesions in small pancreatic ducts

Usually not apparent grossly

IPMN

Mucin-producing neoplasm in larger pancreatic ducts

Can distend the main or branch ducts

MCN

Mucin-filled cystic neoplasm

Characteristically associated with ovarian-type stroma

Three different anatomic settings share a clinically important preinvasive phase.

Slide 5 · Site and macroscopic visibility

Lesion

Primary structure

Detection pattern

PanIN

Small pancreatic ducts

Often microscopic

IPMN

Main or branch pancreatic duct

Duct-centered cystic mass

MCN

Mucinous cyst with stromal wall

Macroscopic cystic mass

Slide 6 · Preinvasive lesions and their outcomes

Duct or cyst epithelium

Neoplastic change

Noninvasive precursor

Variable dysplasia

Additional alterations

Accumulating abnormalities

Invasive carcinoma

Loss of confinement

Schematic: Progression is possible, not inevitable for any individual precursor.

Slide 7 · PanIN: The dominant precursor route

More than 85% of pancreatic cancers are thought to arise from PanIN

Interpretation

The remaining cancers are considered to originate in precursor cystic lesions. This is a proposed origin distribution, not a prediction for any given PanIN.

Slide 8 · PanIN arises in small pancreatic ducts

PanIN = pancreatic intraepithelial neoplasia.

It is a noninvasive epithelial lesion involving small ducts.

Most PanIN lesions are microscopic rather than grossly visible.

Its grading is determined by epithelial morphology.

Slide 9 · Duct epithelial transformation — schematic

Normal duct

Organized epithelial lining around a patent lumen

Low-grade PanIN

Early epithelial atypia within the duct

High-grade PanIN

More advanced atypia without stromal invasion

Schematic, not histology

Slide 10 · Four lines of evidence for PanIN progression

Molecular concordance

PanIN shares genetic and epigenetic alterations with invasive cancer

Anatomic association

PanIN often occurs near an infiltrating pancreatic carcinoma

Experimental evolution

PanIN precedes invasive disease in engineered mouse models

Longitudinal observation

Individual case reports document later invasive carcinoma

Slide 11 · Molecular evidence connects PanIN and cancer

Preinvasive PanIN and invasive carcinoma share molecular alterations

Interpretation

This supports a clonal progression model rather than treating PanIN as merely an unrelated reactive duct change.

Slide 12 · PanIN adjacent to infiltrating cancer

PanIN frequently is identified in pancreatic parenchyma next to invasive carcinoma.

Spatial coexistence is supportive evidence for a precursor relationship.

Coexistence alone does not establish that every nearby PanIN generated that cancer.

Slide 13 · PanIN in different clinical settings

Finding

Source-described pattern

Isolated low-grade PanIN

Can occur in pancreata of elderly individuals

High-grade PanIN without invasive carcinoma

Rarely observed

PanIN next to infiltrating carcinoma

Frequently identified

Association does not establish individual-lesion destiny.

Slide 14 · Why high-grade PanIN is significant

High-grade PanIN is seldom isolated from invasive disease

Interpretation

The strong association with infiltrating carcinoma makes it a particularly consequential noninvasive lesion.

Slide 15 · Experimental evidence: Mouse models

Genetically engineered models reproduce PanIN before invasive pancreatic cancer.

The temporal sequence strengthens biological plausibility.

Animal progression is evidence for the pathway, not a substitute for human longitudinal data.

Slide 16 · Human temporal evidence remains limited

Isolated clinical reports describe PanIN followed by invasive carcinoma.

These observations demonstrate that temporal progression can occur.

They do not supply a population-level probability that a single PanIN will progress.

Slide 17 · What makes a precursor claim persuasive?

Shared changes

Molecular concordance

Coexistence

PanIN near carcinoma

Correct sequence

Model or follow-up

Plausible pathway

Noninvasive → invasive

Different evidence types support distinct aspects of causation.

Slide 18 · PanIN is classified by grade

Low-grade and high-grade PanIN

Interpretation

The current binary grading scheme groups several previously separate low-grade categories and reserves high grade for severe neoplastic atypia.

Slide 19 · Current and historical PanIN terminology

Current system

Former terminology

Low-grade PanIN

PanIN-1A, PanIN-1B, PanIN-2

High-grade PanIN

PanIN-3

High-grade PanIN

Also described as carcinoma in situ

Slide 20 · Low-grade PanIN is not invasive cancer

Low-grade PanIN is a preinvasive epithelial lesion

Interpretation

It can occur incidentally in older individuals, so its presence alone does not establish an existing invasive carcinoma.

Slide 21 · High-grade PanIN: Carcinoma in situ

Severe epithelial neoplasia that remains intraductal

Interpretation

Despite the term “carcinoma,” carcinoma in situ is distinguished from stromally invasive ductal adenocarcinoma.

Slide 22 · Grading visual: Increasing architectural atypia

Normal duct

Uniform cell organization

Low-grade PanIN

Duct-confined epithelial abnormality

High-grade PanIN

Greater cytologic and architectural atypia

Schematic morphology only; Not a diagnostic photomicrograph.

Slide 23 · Histologic boundary: Noninvasive versus invasive

Noninvasive PanIN

Neoplastic lining within a duct

Duct boundary

Epithelial confinement

Invasive carcinoma

Tumor cells infiltrate tissue

Native schematic of the conceptual boundary; Not a literal basement membrane image.

Slide 24 · PanIN epithelial telomeres shorten

Marked telomere shortening occurs in PanIN

Interpretation

This alteration can predispose cells to chromosomal abnormalities during neoplastic progression.

Slide 25 · Telomere dysfunction: Proposed consequence

Telomere shortening

Present in PanIN epithelial cells

Chromosomal instability

Accumulation may become easier

Additional alterations

Potential for progression

The source describes predisposition (“may”), not deterministic progression.

Slide 26 · PanIN progression: Multistep framework

Normal duct

Initial state

Low-grade PanIN

Early alterations

High-grade PanIN

Additional suppressor loss

Invasion

Malignant infiltration

A conceptual sequence; The genetic order is not fixed.

Slide 27 · Early molecular event: KRAS

Activating KRAS mutations appear early in PanIN

Interpretation

KRAS is the most frequently altered oncogene in pancreatic ductal adenocarcinoma; The early PanIN model links its activation to neoplastic initiation.

Slide 28 · KRAS: Oncogene activation

KRAS

Chromosome 12p

MOLECULAR EFFECT

Activating point mutation

Early PanIN

Telomeres, KRAS

Intermediate

P16/CDKN2A loss

High-grade PanIN

TP53 / SMAD4 / BRCA2

Invasion

More altered clones

Caution: The number of cooperating alterations matters more than their exact order.

Slide 35 · Genetic events do not follow one rigid clock

Accumulation matters more than mutation order

Interpretation

Robbins explicitly cautions that the progression diagram describes a general temporal trend, not an invariant molecular sequence.

Slide 36 · Classes of alteration in carcinogenesis

Slide 37 · KRAS in established pancreatic cancer

Activating KRAS mutations occur in more than 90% of cases

Interpretation

This frequency refers to invasive pancreatic cancer; It must not be interpreted as a measured prevalence in every grade of PanIN.

Slide 38 · Alteration frequencies in invasive carcinoma

Gene

Source-reported frequency

Functional category

KRAS

>90%

Oncogenic GTPase signaling

TP53

70–75%

DNA damage response

SMAD4

55%

TGF-β tumor suppression

CDKN2A

30%

Cell-cycle regulation

Invasive cancer frequencies, not stage-specific PanIN rates.

Slide 39 · KRAS and candidate targeted therapy

Mutant RAS inhibitors have become available.

Ongoing trials in patients with KRAS-mutant pancreatic cancer.

This is therapeutic context for invasive cancer, not a recommended treatment for incidental PanIN.

Slide 40 · Tumor suppressors act through different pathways

CDKN2A, TP53, and SMAD4 are not interchangeable

Interpretation

They regulate cell-cycle control, DNA damage responses, and TGF-β signaling, respectively. Multiple defects can cooperate.

Slide 41 · CDKN2A, TP53, and SMAD4 roles

CDKN2A

P16: Negative cell-cycle regulation

ARF: Second encoded tumor suppressor

TP53

Response to DNA damage

Late alteration in PanIN model

SMAD4

Mediator in TGF-β pathway

Later alteration in PanIN model

Slide 42 · Genetics and epigenetics cooperate

Changes in DNA sequence and gene expression act together

Interpretation

Pancreatic carcinogenesis involves both mutations and pathogenic epigenetic alterations, not merely a linear list of gene mutations.

Slide 43 · Promoter hypermethylation silences suppression

Promoter hypermethylation

Epigenetic change

CDKN2A expression

Transcriptional silencing

Growth control

Tumor suppressor effect reduced

This is a gene-regulatory schematic, not proof that all CDKN2A losses occur by methylation.

Slide 44 · Promoter hypomethylation may activate expression

Promoter hypomethylation

Epigenetic change

GATA6 / BRD4

Overexpression

Carcinoma biology

Oncogenic programs altered

Based on source examples of epigenetic changes in invasive pancreatic cancer.

Slide 45 · Expression subtypes in established carcinoma

Expression profiling identifies basal-like and classic pancreatic cancer subtypes.

Basal-like tumors are described as highly aggressive.

The classic subtype has a comparatively more favorable prognosis.

Mixed composition and treatment-associated plasticity complicate a fixed binary view.

Slide 46 · Basal-like and classic expression programs

Subtype

Textbook-described behavior

Basal-like

Highly aggressive

Classic

Somewhat more favorable prognosis

Mixed/plastic tumors

Different proportions; Can change under chemotherapy

Context on invasive cancer; Do not apply these labels as established PanIN grades.

Slide 47 · PanIN in one conceptual map

Anatomic setting

Small ducts

Usually microscopic

Biology

Early telomere and KRAS changes

Additional suppressor losses

Clinical meaning

Graded low or high

High grade is strongly associated with invasive cancer

Slide 48 · Not every precursor is microscopic

IPMN and MCN represent macroscopic mucinous pathways

Interpretation

They are distinct from PanIN in architecture and clinical detection, but share the possibility of progression to invasive cancer.

Slide 49 · Macroscopic mucinous pathways

Feature

IPMN

MCN

Structure

Larger pancreatic ducts

Mucin-filled cystic lesion

Characteristic clue

Main/branch duct involvement

Ovarian-type stroma

Invasive potential

Yes

Slide 50 · Mucinous cystic neoplasm: Morphology

MCNs have relatively large mucin-filled cystic spaces.

Their cavities contain thick, tenacious mucin.

The lining is mucin-producing columnar epithelium.

A dense ovarian-type stroma is characteristic.

Slide 51 · Ovarian-type stroma defines MCN morphology

Dense stroma resembling ovarian stroma underlies the cyst lining

Interpretation

The stromal component frequently expresses estrogen and progesterone receptors and may express inhibin.

Slide 52 · MCN: Patient and organ distribution

Close to 95% arise in females,.

MCN usually involves the pancreatic tail.

These are often slow-growing and painless masses.

Because MCN is precancerous, noninvasive versus invasive status matters.

Slide 53 · MCN molecular profile

Alteration

Source description

KRAS activation

Approximately half of MCNs

RNF43 loss-of-function

Reported in up to one-third

TP53 / SMAD4

Typically observed in invasive tumors arising from MCN

Slide 54 · MCN: Potential progression pathway

Mucinous cyst

Ovarian-type stroma

Noninvasive MCN

Mucinous lining

Invasive carcinoma

May arise in a subset

Noninvasive lesions are typically curable after complete surgical resection according to the source.

Slide 55 · The point of detecting noninvasive MCN

Removing a noninvasive MCN can be curative

Interpretation

The biologic importance lies in preventing progression to an infiltrating carcinoma; The source emphasizes prompt detection and treatment before invasion.

Slide 56 · Intraductal papillary mucinous neoplasm

IPMNs are mucin-producing neoplasms of large pancreatic ducts.

They involve the main pancreatic duct or one of its branches.

Ductal involvement helps distinguish IPMN from MCN.

IPMN can develop an invasive carcinoma.

Slide 57 · IPMN follows pancreatic duct anatomy

Main pancreatic duct

May contain papillary tumor

Branch ducts

Can also be involved

Duct dilation

Visible cystic/ductal lesion

Schematic only; No main-versus-branch-specific cancer-risk ranking is assumed.

Slide 58 · IPMN: Typical distribution

IPMNs are described as more frequent in males than MCNs.

They tend to involve the pancreatic head.

Up to 20% are multifocal.

The absence of ovarian-type stroma distinguishes IPMN from MCN.

Slide 59 · IPMN: Source-described genetic alterations

Alteration

Frequency / context

KRAS activation

Approximately 80%

RNF43 loss-of-function

Up to 50%

GNAS activation

Approximately two-thirds

BRAF alteration

About 10%

Slide 60 · GNAS is particularly informative in IPMN

GNAS mutations occur in about two-thirds of IPMNs

Interpretation

The source states these oncogenic mutations were not found in the other pancreatic cysts discussed; This is a distinctive molecular clue.

Slide 61 · Late molecular changes in invasive IPMN

TP53 and SMAD4 alterations typically accompany invasion

Interpretation

The described pattern distinguishes common driver events in noninvasive IPMN from genetic changes associated with its invasive progression.

Slide 62 · IPMN evolution: Distinguish stages

Ductal mucinous lesion

KRAS / GNAS / RNF43 may occur

Noninvasive IPMN

Variable epithelial dysplasia

Invasive carcinoma

TP53 / SMAD4 changes typical

Source identifies these mutation associations; The diagram does not imply every IPMN progresses.

Slide 63 · IPMN versus MCN: Discriminating features

Criterion

IPMN

MCN

Anatomic relationship

Main / branch duct

Mucin-filled cyst

Stroma

No ovarian-type stroma

Dense ovarian-type stroma

Usual site

Pancreatic head

Pancreatic tail

Demographic trend

More often male

Almost always female

Slide 64 · GNAS and RNF43 distinguish pathways

Gene

IPMN

MCN

GNAS

~Two-thirds

Not described in other cysts

RNF43

Up to 50%

Up to one-third

KRAS

~80%

~50%

TP53, SMAD4

Usually invasive transition

Usually invasive MCN

Values refer to lesions in the source; Not population screening performance.

Slide 65 · Mucinous versus serous cystic lesions

Feature

Mucinous precursors

Serous cystic neoplasm

Malignant potential

Can progress to invasion

Almost always benign

Cyst content

Mucin

Thin, clear fluid

Typical molecular clue

KRAS ± GNAS / RNF43

VHL inactivation

Slide 66 · Pseudocyst versus mucinous neoplasm

Diagnostic property

Pseudocyst

Mucinous neoplasm

Origin

Post-injury necrosis

Neoplastic epithelium

Lining

No true epithelium

Epithelial lining present

Wall

Fibrous / granulation tissue

Defined cyst and neoplastic lining

Precursor status

Not a carcinoma precursor

IPMN / MCN may be precancerous

Slide 67 · A pancreatic cyst is not automatically premalignant

Etiology and epithelial lining determine the lesion category

Interpretation

Serous cystic neoplasms are usually benign, pseudocysts are nonneoplastic, and IPMN/MCN are the important mucinous precursors in this section.

Slide 68 · Three precursor classes — consolidated view

Property

PanIN

IPMN

MCN

Size/site

Microscopic small duct

Main/branch duct

Gross cyst

Defining morphology

Ductal dysplasia

Papillary mucinous duct tumor

Mucinous epithelium + ovarian stroma

Genetic theme

KRAS early; Late suppressors

KRAS, GNAS, RNF43

KRAS, RNF43

Can become invasive?

Yes

Slide 69 · Why identifying the precursor phase matters

The invasive carcinoma is typically clinically advanced at detection.

A visible cystic precursor may create an opportunity for intervention before invasion.

Noninvasive IPMN and MCN are described as almost always curable after resection.

PanIN often remains microscopic, limiting direct detection.

Slide 70 · Do not confuse a cancer risk factor with a precursor

A risk factor increases probability; A precursor is an epithelial lesion

Interpretation

Examples of risk context include chronic pancreatitis, smoking, and inherited predisposition. PanIN, IPMN, and MCN are pathologic precursor lesions.

Slide 71 · Inherited predisposition is a separate dimension

Context

Illustrative genes / findings

Cancer predisposition

BRCA2, ATM; Other DNA-repair genes

Precursor molecular progression

Somatic KRAS, CDKN2A, TP53, SMAD4

Overlap

DNA repair abnormalities can contribute to carcinogenesis

Source emphasizes inherited DNA-repair predisposition and somatic alterations; These are distinct analytic levels.

Slide 72 · Applied vignette: Microscopic pancreatic duct

TEACHING VIGNETTE

A small duct has atypical epithelium confined within the duct, with no stromal invasion. The report describes high-grade dysplasia.

Which class of precursor does this fit?

Slide 73 · Case interpretation: A high-grade small-duct lesion

High-grade PanIN, not invasive ductal adenocarcinoma

Interpretation

An epithelial lesion confined to the small duct meets the conceptual description of high-grade PanIN; Invasion requires infiltrative tumor beyond the preexisting duct.

Slide 74 · Applied vignette: Mucinous tail cyst

TEACHING VIGNETTE

A mucin-filled cyst in the pancreatic tail occurs in an adult woman. Histology shows a mucinous epithelial lining and dense ovarian-type stroma.

Which precursor is most likely?

Slide 75 · Case interpretation: Ovarian-type stroma

Mucinous cystic neoplasm

Interpretation

The ovarian-type stroma is the decisive morphologic discriminator. Duct-centered IPMN does not have this characteristic stromal component.

Slide 76 · Applied vignette: Main-duct mucinous lesion

TEACHING VIGNETTE

A papillary mucin-producing lesion distends the main pancreatic duct. No dense ovarian-type stroma is present.

Which precursor fits the duct-centered lesion?

Slide 77 · Case interpretation: Main-duct disease

Intraductal papillary mucinous neoplasm

Interpretation

Main-duct involvement and absence of ovarian-type stroma point to IPMN rather than MCN.

Slide 78 · Synthesis: Pathways converge on invasion

PanIN

Microscopic small duct

IPMN

Mucinous large duct

MCN

Mucinous ovarian-stroma cyst

Invasive cancer

Potential shared outcome

Conceptual convergence; Not every precursor becomes invasive.

Slide 79 · Five distinctions worth retaining

PanIN: Small ducts, microscopic, graded low versus high.

IPMN: Mucinous neoplasm of main or branch ducts; GNAS is characteristic.

MCN: Mucinous cyst with dense ovarian-type stroma, often in the tail.

KRAS is early in classic PanIN progression; TP53/SMAD4 are later.

Presence of epithelial invasion—not high-grade dysplasia alone—defines invasive cancer.

Slide 80 · Source and scope

Primary reference

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th edition (2026). Chapter 19: The Pancreas.

Teaching scope

PanIN biology and progression, related mucinous cystic precursors, and selected molecular context for pancreatic ductal adenocarcinoma.